RxDoctor Payments Data

Ryan Allen, DO

Family Medicine · Santa Maria, CANPI 1265417752

Payments from drug & device makers

$12,528in general payments, 2019–2025

Across 732 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$950
  • GSK$913
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$12,513100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,528 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$118,894
Medicare patients
227
Services billed
1,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$92,478
JardianceEmpagliflozin57$69,082
RybelsusSemaglutide35$40,306
TrulicityDulaglutide20$34,596
EliquisApixaban33$33,755
FarxigaDapagliflozin Propanediol22$32,978
OxycontinOxycodone Hcl13$30,291
Janumet XrSitagliptin Phos/Metformin Hcl19$30,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$25,029
Tresiba Flextouch U-100Insulin Degludec21$18,037
Breo ElliptaFluticasone/Vilanterol35$17,235
XareltoRivaroxaban11$13,595
JanuviaSitagliptin Phosphate17$13,334
Rosuvastatin Calcium165$4,038
Metoprolol Succinate203$3,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,794$132,78392 claims
Boehringer IngelheimJardiance$1,346$69,08257 claims
MerckJanumet Xr, Januvia$160$43,33536 claims
GSKTrelegy Ellipta, Breo Ellipta$913$42,26467 claims
PfizerEliquis, Paxlovid$1,098$36,61352 claims
Lilly USA, LLCTrulicity$950$34,59620 claims
AstraZenecaFarxiga$1,102$32,97822 claims
Johnson & JohnsonXarelto$498$13,59511 claims
AbbVieSynthroid$727$1,32241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →